Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: A 36-month randomized controlled clinical trial

Journal of Managed Care Pharmacy

Volumn 21, Issue 1, 2015, Pages 66-75

  Obreli Neto, Paulo Roque ^a   Marusic, Srecko ^b   Guidoni, Camilo Molino ^c   Baldoni, André de Oliveira ^a   Renovato, Rogério Dias ^d   Pilger, Diogo ^e   Cuman, Roberto Kenji Nakamura ^f   Pereira, Leonardo Régis Leira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University of Zagreb   (Croatia)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

^d UNIVERSIDADE ESTADUAL DE MATO GROSSO DO SUL   (Brazil)

^e FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^f STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE CONTROL; DRUG COST; ECONOMIC EVALUATION; EMERGENCY WARD; FEMALE; GENERAL PRACTITIONER; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NURSE; PHARMACEUTICAL CARE; PHARMACIST; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VERY ELDERLY; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; PATIENT ATTITUDE; PHARMACY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; GLUCOSE BLOOD LEVEL; HEALTH CARE UTILIZATION; OUTCOME ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGED; BRAZIL; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIABETES MELLITUS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PHARMACEUTICAL SERVICES; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84925324767     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.1.66     Document Type: Article

References (39)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013. Available at: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed December 8, 2014.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23.
3. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1c, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36(8):2271-79. Available at: http://care.diabetesjournals.org/content/36/8/2271.full.pdf+html. Accessed December 8, 2014.
4. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27(5):963-75.
5. Moreira GC, Cipullo JP, Martin JF, et al. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study. J Hypertens. 2009;27(9):1900-07.
6. Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):39-43. Available at: http://care.diabetesjournals.org/content/37/1/39.full.pdf+html. Accessed December 8, 2014.
7. de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):24-30. Available at: http://care.diabetesjournals.org/content/37/1/24.full.pdf+html. Accessed December 8, 2014.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27454/pdf/405.pdf. Accessed December 8, 2014.
9. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412-19. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27455/pdf/412.pdf. Accessed December 8, 2014.
10. Nichols GA, Joshua-Gotlib S, Parasuraman S. Independent contribution of A1c, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. J Gen Intern Med. 2013;28(5):691-97. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631078/pdf/11606_2012_Article_2320.pdf. Accessed December 8, 2014.
11. Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16(4):264-75. Available at: http://www.amcp.org/data/jmcp/264-275.pdf.
12. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-86. Available at: http://circ.ahajournals.org/content/119/3/480.full.pdf+html. Accessed December 8, 2014.
13. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3): 533-43.
14. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001;21(11):1337-44.
15. Houle SK, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacistmanaged hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Pharmacotherapy. 2012;32(6):527-37.
16. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: longterm clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (2003). 2003;43(2):173-84.
17. Fera T, Bluml BM, Ellis WM. Diabetes Ten City Challenge: final economic and clinical results. J Am Pharm Assoc (2003). 2009;49(3):383-91.
18. Aguiar PM, Balisa-Rocha BJ, Brito GC, Lyra DP Jr. Pharmaceutical care program for elderly patients with uncontrolled hypertension. J Am Pharm Assoc (2003). 2012;52(4):515-18.
19. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-71. Available at: http://jama.jamanetwork.com/article.aspx?articleid=204402. Accessed December 8, 2014.
20. Lee VW, Yi PT, Kong KW, Chan PK, Kwok FL. Impact of pharmacy outreach services on blood pressure management in the elderly community of Hong Kong. Geriatr Gerontol Int. 2013;13(1):175-81.
21. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2011;34(1):20-26. Available at: http://care.diabetesjournals.org/content/34/1/20.full.pdf+html. Accessed December 8, 2014.
22. Chung N, Rascati K, Lopez D, Jokerst J, Garza A. Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population. J Manag Care Pharm. 2014;20(9);914-19. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18468.
23. Correr CJ, Pontarolo R, Wiens A, et al. [Economic evaluation of pharmacotherapeutic follow-up in type 2 diabetes mellitus patients in community pharmacies]. Arq Bras Endocrinol Metabol. 2009;53(7):825-33. [Article in Portuguese]. Available at: http://www.scielo.br/pdf/abem/v53n7/06.pdf. Accessed December 8, 2014.
24. Borges AP, Guidoni CM, Freitas OD, Pereira LR. Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. Arq Bras Endocrinol Metabol. 2011;55(9):686-91. Available at: http://www.scielo.br/pdf/abem/v55n9/03.pdf. Accessed December 8, 2014.
25. Brasil. República Federativa do Brasil. Lei n. 8080, 19 de setembro de 1990. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização e o funcionamento dos serviços correspondentes e dá outras providências. Available at: http://portal.in.gov.br/. Accessed December 8, 2014.
26. Brasil. República Federativa do Brasil. Lei n. 8142, de 28 de dezembro de 1990. Dispõe sobre a participação da comunidade na gestão do Sistema único de Saúde (SUS) e sobre as transferências intergovernamentais de recursos financeiros na área da saúde e dá outras providências. Available at: http://portal.in.gov.br/. Accessed December 8, 2014.
27. Sociedade Brasileira de Cardiologia-SBC; Sociedade Brasileira de Hipertensão-SBH; Sociedade Brasileira de Nefrologia-SBN. [IV Brazilian Guidelines in Arterial Hypertension]. Arq Bras Cardiol. 2007;89(3):e24-79. [Article in Portuguese]. Available at: http://www.scielo.br/pdf/abc/v82s4/03.pdf. Accessed December 8, 2014.
28. Brazilian Society of Diabetes. Brazilian Society of Diabetes' Guidelines 2009. Itapevi, SP: Araújo Silva Farmacêutica; 2009.
29. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice: The Clinician's Guide. New York: McGraw-Hill; 2004.
30. Diabetes Control and Complication Trials Research Group. Lifetime benefits and costs of intensive therapy as practiced in Diabetes Control and Complications Trial. JAMA. 1996;276(17):1409-15.
31. Shin AY, Porter PJ, Wallace MC, Naglie G. Quality of life of stroke in younger individuals. Utility assessment in patients with arteriovenous malformations. Stroke. 1997;28(12):2395-99. Available at: http://stroke.ahajournals.org/content/28/12/2395.long. Accessed December 8, 2014.
32. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke. 1992;23(11):1551-55. Available at: http://stroke.ahajournals.org/content/23/11/1551.long. Accessed December 8, 2014.
33. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13(2):161-65.
34. Nease RF Jr, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA. 1995;273(15):1185-90.
35. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-89. Available at: http://jama.jamanetwork.com/article.aspx?articleid=193448. Accessed December 8, 2014.
36. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-34.
37. Byrnes PD. Why haven't I changed that? Therapeutic inertia in general practice. Aust Fam Physician. 2011;40(1-2):24-28. Available at: http://www.racgp.org.au/download/documents/AFP/2011/JanFeb/201101byrnes.pdf. Accessed December 8, 2014.
38. Rothman RL, So SA, Shin J, et al. Labor characteristics and program costs of a successful diabetes disease management program. Am J Manag Care. 2006;12(5):277-83. Available at: http://www.internetgroup.ca/clientnet_new/docs/Labor%20Characteristics%20and%20Program%20Costs.pdf. Accessed December 8, 2014.
39. Cooper H, Booth K, Fear S, Gill G. Chronic disease patient education: lessons from meta-analyses. Patient Educ Couns. 2001;44(2):107-17.